Evotec and Carna Biosciences Collaborate on Indigo Platform

HAMBURG–()–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
today announced a strategic collaboration with Carna Biosciences,
Incorporated (“Carna”). Carna will access Evotec’s INDiGO platform to
accelerate the development of its programme CB-1763, which is being
developed for the treatment of blood cancer, through to the submission
of an Investigational New Drug Application (“IND”) with the U.S. Food
and Drug Administration.

“We are excited to initiate IND-enabling studies for our next-generation
non-covalent BTK inhibitor, CB-1763, in collaboration with Evotec”, said
Dr Masaaki Sawa, Chief Scientific Officer at Carna Biosciences. “We’ve
been working with Evotec from last year and found they are a really
reliable partner. We believe Evotec’s INDiGO programme and their team
will help us to accelerate the development of our CB-1763 and we are
confident that we will achieve our goal to reach IND-filing in the first
half of 2019.”

Dr Mario Polywka, Chief Operating Officer of Evotec, added: “This
development of Carna’s key project directly reflects the success of our
comprehensive and industry-unique INDiGO service. We are delighted to
support Carna’s CB-1763 inhibitor programme, an innovative approach to
blood cancer, through to the clinic. Additionally, working with Carna
also highlights our increasing presence in the Japanese market.”

Carna has another reversible BTK inhibitor in pre-clinical development,
AS-871, a novel non-covalent BTK inhibitor targeting autoimmune
diseases. AS-871 is also undergoing IND-enabling studies in
collaboration with Evotec.

About Evotec’s INDiGO platform The INDiGO platform is a key
value-generating component of Evotec’s broad EVT Execute business
segment. INDiGO accelerates early drug candidates into the clinic by
reducing time from nomination to regulatory submission in 52 weeks, and
under circumstances, even less. We achieve accelerated development by
tightly integrating traditional drug silos into a single project managed
under one roof. The programme has been proven to reduce time and cost
while achieving a quality data package for CTA/IND level regulatory

Evotec’s INDiGO projects are managed by our most experienced, dedicated
project managers and leading world-class drug development professionals
implementing tailored development strategies designed specifically for
the molecule, therapeutic area and strategic needs. The project plan is
designed to integrate development areas: API Manufacture, Formulation
Development, Clinical Supply, Safety Assessment, DMPK, Bioanalysis
Studies and Regulatory Submission Documents Preparation.


Carna Biosciences is a biopharmaceutical company focused on the
discovery and development of kinase inhibitor drugs to address serious
unmet medical needs. Carna has intensively focused its research efforts
primarily in the areas of oncology and autoimmune/inflammation, where
the company believes its extensive expertise in kinases can be most
effectively leveraged. Taking advantage of Carna’s proprietary platform
technologies and highly focused kinase expertise, the company continues
to challenge to identify and develop innovative drugs. Carna is a
publicly traded company in the JASDAQ of the Tokyo Stock Exchange with
securities code 4572. For more information, please visit www.carnabio.com.


CB-1763 is a highly selective, orally bioavailable, non-covalent
inhibitor of Bruton’s tyrosine kinase (BTK) with a potential application
in the treatment of blood cancer. Recent studies have indicated that the
emergence of BTK mutations causes ibrutinib resistance. A selective and
non-covalent BTK inhibitor is therefore highly demanded to overcome the
emerging unmet medical need of ibrutinib resistance. CB-1763 is a
next-generation non-covalent BTK inhibitor, designed to inhibit both BTK
wild type and BTK C481 mutants in a highly selective and reversible



Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with
leading pharmaceutical and biotechnology companies, academics, patient
advocacy groups and venture capitalists. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic to meet the industry’s
need for innovation and efficiency in drug discovery (EVT Execute). The
Company has established a unique position by assembling top-class
scientific experts and integrating state-of-the-art technologies as well
as substantial experience and expertise in key therapeutic areas
including neuroscience, diabetes and complications of diabetes, pain and
inflammation, oncology and infectious diseases. On this basis, Evotec
has built a broad and deep pipeline of more than 80 partnered product
opportunities at clinical, pre-clinical and discovery stages (EVT
Innovate). Evotec has established multiple long-term discovery alliances
with partners including Bayer, CHDI, Sanofi or UCB and development
partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer
in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information, please go to www.evotec.com
and follow us on Twitter @EvotecAG.


Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates
or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on
which any such statement is based.

Language:     English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222




ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated
Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich,
Stuttgart, Tradegate Exchange

Source link

Leave a Reply

Your email address will not be published.